Clinical Trial Update: Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) [Phase 2]

View source ↗

Summary

Phase 2 MDT-BRIDGE trial evaluating neoadjuvant durvalumab with platinum-based chemotherapy in resectable or borderline resectable Stage IIB-IIIB non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Platinum-based chemotherapy (cisplatin or carboplatin)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING